GRFS · NASDAQ
Grifols SA (GRFS) Stock Price & Fundamentals
Grifols SA (GRFS) closed at $381.78 on Oct 9, 2026, up 0.17% from the previous close of $381.13.
Share price, past year
1Y −10.17%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $381.78 |
| Sep 30, 2026 | $374.20 |
| Aug 31, 2026 | $402.22 |
| Jul 31, 2026 | $397.23 |
| Jun 30, 2026 | $382.08 |
| May 29, 2026 | $377.77 |
| Apr 30, 2026 | $396.94 |
| Mar 31, 2026 | $398.24 |
| Feb 27, 2026 | $423.80 |
| Jan 30, 2026 | $455.03 |
| Dec 31, 2025 | $438.07 |
| Nov 28, 2025 | $454.93 |
| Oct 31, 2025 | $441.09 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- —
- Dividend yield
- —
- 52-week range
- $362.25 – $474.42
Market cap, P/E and dividend yield aren't shown for Grifols SA yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US, and report in euros.
Financials
Grifols SA reported revenue of €7.21B for fiscal 2024, up 9.41% from fiscal 2023.
Figures are in euros (EUR), as Grifols SA reports them to the SEC.
Grifols SA earned net income of €156.92M in fiscal 2024, a net margin of 2.2%.
Fiscal 2024 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2024ended Dec 31, 2024 | €7.21B | +9.4% | €156.92M | 2.2% | €0.23 | €669.63M |
| FY2023ended Dec 31, 2023 | €6.59B | +8.7% | €42.32M | 0.6% | €0.06 | −€5.75M |
| FY2022ended Dec 31, 2022 | €6.06B | +22.9% | €185.04M | 3.1% | €0.27 | −€285.23M |
| FY2021ended Dec 31, 2021 | €4.93B | −7.6% | €188.73M | 3.8% | €0.28 | €349.60M |
| FY2020ended Dec 31, 2020 | €5.34B | +4.7% | €618.55M | 11.6% | €0.90 | €830.18M |
| FY2019ended Dec 31, 2019 | €5.10B | +13.6% | €625.15M | 12.3% | €0.91 | €258.55M |
| FY2018ended Dec 31, 2018 | €4.49B | +3.9% | €596.64M | 13.3% | €0.87 | €505.45M |
| FY2017ended Dec 31, 2017 | €4.32B | +6.6% | €662.70M | 15.4% | €0.97 | €590.24M |
| FY2016ended Dec 31, 2016 | €4.05B | +2.9% | €545.46M | 13.5% | €0.80 | €303.86M |
| FY2015ended Dec 31, 2015 | €3.93B | — | €532.15M | 13.5% | €0.78 | €220.19M |
Company profile
- Name
- Grifols SA
- Ticker
- GRFS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1585 Broadway, Suite 2376, New York, NY 10036
- SEC CIK
- 0001438569
Recent SEC filings
- Apr 17, 2026
- Apr 11, 2025
- Apr 19, 2024
- Apr 18, 2023
- Apr 29, 2022
- Apr 9, 2021
- Apr 6, 2020
- Apr 23, 2019
Related stocks
Grifols SA's industry, as the SEC classifies it, is Pharmaceutical Preparations. The companies in it closest to Grifols SA in revenue are Lakefront Biotherapeutics NV, Evotec SE and Ascendis Pharma A.
ETFs that hold Grifols SA
Of the ETFs and funds on Laurel, iShares Biotechnology ETF (IBB) holds the most Grifols SA shares by value: 0.12% of the fund, as of its latest report to the SEC.
Frequently asked questions
What is Grifols SA's stock price?
Grifols SA (GRFS) closed at $381.78 on Oct 9, 2026, up 0.17% from the previous close of $381.13.
How much revenue does Grifols SA make?
Grifols SA reported revenue of €7.21B for fiscal 2024, up 9.41% from fiscal 2023.
Sources and methodology
Fundamentals come from Grifols SA's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures